Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004

Cannabis and Cannabinoid Research

Volumn 2, Issue 1, 2017, Pages 1-4

  Grotenhermen, Franjo ^a   Russo, Ethan ^b   Zuardi, Antonio Waldo ^c  

^a Chemiepark Knapsack   (Germany)

^b PHYTECS   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cannabidiol; cannabinoid; medical use; route of administration (oral vs. transdermal); safety; THC

Indexed keywords

AMISULPRIDE; CANNABIDIOL; CLOBAZAM; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; PROLACTIN; TETRAHYDROCANNABINOL;

ANXIETY; ARTICLE; BODY WEIGHT GAIN; COGNITION; COGNITIVE DEFECT; CONVULSION; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; HYPERPROLACTINEMIA; PARKINSON DISEASE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOCIAL PHOBIA; SOMNOLENCE; STOMACH JUICE; WITHDRAWAL SYNDROME;

EID: 85058965085     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0036     Document Type: Article

References (21)

1. Grotenhermen F, Gebhardt K, Berger M. Cannabidiol [book in German]. Nachtschatten Verlag, Solothurn, Switzerland, 2015 (1st edition), 2016 (2nd revised edition).
2. Merrick J, Lane B, Sebree T, et al. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis Cannabinoid Res. 2016;1:102-112.
3. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66:234-246.
4. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278.
5. Nicholson AN, Turner C, Stone BM, et al. Effect of Delta-9- tetrahydrocannabinol and cannabidiol on nocturnal sleep and earlymorning behavior in young adults. J Clin Psychopharmacol. 2004;24:305-313.
6. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta- 9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764-774.
7. Consroe P, Carlini EA, Zwicker AP, et al. Interaction of cannabidiol and alcohol in humans. Psychopharmacology (Berl). 1979;66:45-50.
8. Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76:245-250.
9. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40:701-708.
10. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36:1219-1226.
11. Zuardi AW, Morais SL, Guimarães FS, et al. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56:485-486.
12. Zuardi AW, Hallak JE, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol. 2006;20:683-686.
13. Zuardi A, Crippa J, Dursun S, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24:135-137.
14. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009;23:979-983.
15. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012;2:e94.
16. Crippa JA, Zuardi AW, Hallak JE. [Therapeutical use of the cannabinoids in psychiatry]. Rev Bras Psiquiatr. 2010;32 Suppl 1:S56-S66.
17. Martin-Santos R, Crippa JA, Batalla A, et al. Acute effects of a single, oral dose of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012;18:4966-4979.
18. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278.
19. Borgwardt SJ, Allen P, Bhattacharyya S, et al. Neural basis of Delta-9- tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry. 2008;64:966-973.
20. Russo EB. Cannabis and Epilepsy: an ancient treatment returns to the fore. Epilepsy Behav. [Epub ahead of print]; DOI: 10.1016/j.yebeh.2016.09.040.
21. Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40:517-522.